| PDF (233kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-293079
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.29307
Beier, Christoph P. ; Schmid, Christina ; Gorlia, Thierry ; Kleinletzenberger, Christine ; Beier, Dagmar ; Grauer, Oliver ; Steinbrecher, Andreas ; Hirschmann, Birgit ; Brawanski, Alexander ; Dietmaier, Christopher ; Jauch-Worley, Tanja ; Kölbl, Oliver ; Pietsch, Torsten ; Proescholdt, Martin A. ; Rümmele, Petra ; Muigg, Armin ; Stockhammer, Günther ; Hegi, Monika 
; Bogdahn, Ulrich ; Hau, Peter
; Bogdahn, Ulrich ; Hau, Peter 
Zusammenfassung
Background: Although Temozolomide is effective against glioblastoma, the prognosis remains dismal and new regimens with synergistic activity are sought for. Methods: In this phase-I/II trial, pegylated liposomal doxorubicin (Caelyx (TM), PEG-Dox) and prolonged administration of Temozolomide in addition to radiotherapy was investigated in 63 patients with newly diagnosed glioblastoma. In phase-I, ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik